Use of proteasome inhibitors to treat ocular disorders

• 收藏
• 分享

专利权人:

Inc.;Accuitis Pharmaceuticals

发明人:

Coulon, Rick

申请号：

AU2016349833

公开号：

AU2016349833A1

申请日:

2016.10.24

申请国别(地区):

AU

年份:

2018

代理人:

摘要：

Hydrocinnamate compounds that exhibit proteasome modulation activity, and in particular, proteasome inhibitory activity, can be used to topically or systemically treat ocular disorders associated with proteasome activity. The hydrocinnamate compounds can be applied to the eye, in any of a variety of ocular formulations, to treat ocular disorders, such as ocular rosacea, diabetic retinopathy, macular degeneration, and dry eye. The hydrocinnamate compounds can also be administered systemically to treat ocular disorders.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/